Competitor Analysis: B7 – CD28/CTLA-4 Pathway

Date: July 1, 2012
Pages: 35
US$ 370.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)

Download PDF Leaflet

Competitor Analysis: B7 – CD28/CTLA-4 Pathway
The present Competitive Intelligence Report about the B7 – CD28/CTLA-4 signaling pathway provides a competitor evaluation in the field of antibodies and fusion proteins targeting the B7 – CD28/CTLA-4 pathway for treatment of autoimmune diseases or cancer as of July 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The report includes a compilation of currently active projects in research and development of antibodies, fusion proteins and binding proteins which target members of the B7 – CD28/CTLA-4 signaling family to treat autoimmune diseases or cancer. In addition, the report lists company-specific R&D pipelines of projects in the B7 – CD28/CTLA-4 pathway. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
  • CTLA-4: Ipilimumab Pipeline
  • CTLA-4: Others
  • CD80/CD86 (B7.1/B7.2): Abatacept Pipeline
  • CD80/CD86 (B7.1/B7.2): Others
  • CD28
  • B7/CD28 Pathway
  • Programmed Death 1 (PD-1) Antagonists
  • PD-1 Ligand (PD-L1) Inhibitors
  • ICOS Antagonists
  • B7-H3 Inhibitors
  • Corporate B7 – CD28/CTLA-4 Pathway Inhibitor R&D Pipelines

Skip to top

Ask Your Question

Competitor Analysis: B7 – CD28/CTLA-4 Pathway
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: